We are live on
!
Find out more
Brown Advisory Portfolio holdings
AUM
$60.9B
1-Year Est. Return
15.24%
This Fund
S&P 500
This Quarter
Est. Return
+9.9%
1 Year Est. Return
+15.24%
3 Year Est. Return
+71.23%
5 Year Est. Return
+86.65%
10 Year Est. Return
+447.92%
AUM
$30.8B
AUM Growth
+$2.83B
(+10%)
Cap. Flow
+$314M
Cap. Flow
% of AUM
1.02%
Top 10 Holdings %
Top 10 Hldgs %
29.43%
Holding
995
New
101
Increased
392
Reduced
278
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$434M |
| 2 |
Estee Lauder
EL
|
+$90.8M |
| 3 |
Visa
V
|
+$90M |
| 4 |
Amphenol
APH
|
+$67.6M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$57.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Idexx Laboratories
IDXX
|
+$409M |
| 2 |
CTXS
Citrix Systems Inc
CTXS
|
+$322M |
| 3 |
Apple
AAPL
|
+$115M |
| 4 |
TotalEnergies
TTE
|
+$31.5M |
| 5 |
Deckers Outdoor
DECK
|
+$27.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.08% |
| 2 | Healthcare | 15.56% |
| 3 | Financials | 11.89% |
| 4 | Industrials | 9.57% |
| 5 | Energy | 9.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
NetApp
NTAP
$32.2B
| $475M | 1.54% |
11,545,664
+129,423
| +1% | +$5.25M |
|
|
27
Gilead Sciences
GILD
$162B
| $470M | 1.52% |
6,257,657
+6,228,123
| +21,088% | +$434M |
|
28
Fossil Group
FOSL
$236M
| $415M | 1.35% |
3,460,728
+22,760
| +0.7% | +$2.81M |
|
29
Cognizant
CTSH
$20.2B
| $389M | 1.26% |
7,702,926
+55,500
| +0.7% | +$2.53M |
|
30
Genpact
G
$5.1B
| $383M | 1.24% |
20,853,301
+142,662
| +0.7% | +$2.66M |
|
|
ANSS
31
DELISTED
Ansys
ANSS
| $349M | 1.13% |
4,000,570
-85,532
| -2% | -$7.34M |
|
|
NATI
32
DELISTED
National Instruments Corp
NATI
| $330M | 1.07% |
10,297,080
+68,002
| +0.7% | +$2.1M |
|
33
ExxonMobil
XOM
$653B
| $287M | 0.93% |
2,838,165
-14,030
| -0.5% | -$1.3M |
|
34
Mastercard
MA
$467B
| $239M | 0.78% |
2,865,240
-113,720
| -4% | -$8.45M |
|
35
Microsoft
MSFT
$2.84T
| $185M | 0.6% |
4,951,111
-77,563
| -2% | -$2.82M |
|
36
Best Buy
BBY
$17.7B
| $175M | 0.57% |
4,382,626
-383,212
| -8% | -$15.7M |
|
37
Wells Fargo
WFC
$261B
| $148M | 0.48% |
3,249,850
+29,567
| +0.9% | +$1.28M |
|
38
Kinder Morgan
KMI
$72.7B
| $142M | 0.46% |
3,932,461
+7,347
| +0.2% | +$257K |
|
39
Occidental Petroleum
OXY
$57.6B
| $122M | 0.4% |
1,340,386
+36,967
| +3% | +$3.38M |
|
40
Berkshire Hathaway Class B
BRK.B
$1.05T
| $120M | 0.39% |
1,016,307
+7,728
| +0.8% | +$894K |
|
41
Merck
MRK
$322B
| $120M | 0.39% |
2,517,818
-489,970
| -16% | -$22.4M |
|
42
Canadian National Railway
CNI
$79.1B
| $120M | 0.39% |
2,104,354
+6,600
| +0.3% | +$363K |
|
43
Warner Bros
WBD
$65.1B
| $114M | 0.37% |
2,468,536
+4,763
| +0.2% | +$206K |
|
|
DD
44
DELISTED
Du Pont De Nemours E I
DD
| $113M | 0.37% |
1,827,266
+28,643
| +2% | +$1.66M |
|
45
IBM
IBM
$193B
| $104M | 0.34% |
577,366
+70,859
| +14% | +$12.2M |
|
46
RTX Corp
RTX
$280B
| $103M | 0.33% |
1,435,959
+2,109
| +0.1% | +$144K |
|
47
Johnson & Johnson
JNJ
$623B
| $101M | 0.33% |
1,104,951
-5,820
| -0.5% | -$536K |
|
48
Walt Disney
DIS
$161B
| $98M | 0.32% |
1,282,068
+7,356
| +0.6% | +$510K |
|
49
JPMorgan Chase
JPM
$925B
| $96.9M | 0.31% |
1,656,218
+23,732
| +1% | +$1.3M |
|
50
United Rentals
URI
$72.6B
| $96M | 0.31% |
1,231,751
+21,437
| +2% | +$1.44M |
|
Similar funds
QCM
Brown Advisory's Q4 2013 Portfolio in Review
As of Q4 2013, Brown Advisory held 995 positions worth $30.8B, up 10% from $28B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Brown Advisory's Q4 2013 filing shows 101 new, 392 increased, 278 reduced and 51 closed positions. Its largest new stake was Plains GP Holdings: 157,910 shares worth $11.3M. The largest sale was Idexx Laboratories, an estimated $409M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 26% a quarter earlier, followed by Healthcare and Financials.
- Brown Advisory's largest Q4 2013 buy was Plains GP Holdings: 157,910 shares worth $11.3M.
- Brown Advisory added most to Gilead Sciences in Q4 2013, an estimated $434M increase.
- Brown Advisory's biggest Q4 2013 reduction was Idexx Laboratories, cutting an estimated $409M.
- Brown Advisory fully exited Ariad Pharmaceuticals Inc in Q4 2013, selling an estimated $19.5M.
- Brown Advisory's ten largest holdings make up 29% of its $30.8B portfolio in Q4 2013.
- Brown Advisory opened 101 new positions and closed 51 in Q4 2013.
- Brown Advisory's portfolio value rose 10% quarter-over-quarter to $30.8B.
Based on Brown Advisory's 13F filing for Q4 2013, filed 11 Feb 2014.